Last updated: March 06, 2006
Bookmark this page
Copyright © Bayer AG
Chairman's Letter
Corporate Structure
Credo
Board of Management
Report of the Supervisory Board
Corporate Governance
Sustainability & Responsibility
Governance Bodies
Organization Chart
Bayer: Science For A Better Life
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Bayer Group Key Data
Ten-Year Financial Summary
Overview of Sales, Earnings and Financial Position
Operating Environment
Performance by Subgroup and Segment
Performance by Region
Value Management
Liquidity and Capital Resources
Earnings Performance
Asset and Capital Structure
Proposal for Distribution of the Profit
Employees
Procurement and Distribution
Research and Development
Sustainable Development
Corporate Social Responsibility
Risk Management
Subsequent Events
Future Perspectives
Management's Statement of Responsibility
Independent Auditor's Report
Statements of Income
Balance Sheets
Statements of Cash Flows
Statements of Recognized Income and Expense
Notes
Awards
Triple-i
New fuel cell production facility
Pharmaceuticals business strenghened
U.S. approval for Nexavar
Innovative fungicide
Dr. Wolfgang Plischke appointed to Management Board
Promising anti- thrombosis drug
Formulation technology for cereal herbicides
New manufacturing process for carbon nanotubes
Bayer and UNEP
Bayer acquires Icon Genetics AG
25 billion tablets produced in Bitterfeld
New production facility in China
Research to protect drinking water
Service Overview
Download Center
Order
Index from A to Z
Glossary
Cover Picture
Index from A to Z
Use the alphabetical index to call up selected pages from the Annual Report.
Select...
Accounting Standards
Acquisitions
Annual Stockholders' Meeting
Asset Structure
Associates
Audit Committee
Audit Fees
Auditor
Awards
Balance Sheet
Bayer Business Services
Bayer CropScience
Bayer HealthCare
Bayer Industry Services
Bayer Innovation GmbH
Bayer MaterialScience
Bayer Stock
Bayer Stock Data
Bayer Technology Services
Board of Management
Bonds
Business Environment
Business Strategy
Capital Expenditures
Capital Structure
Cash Flow
Changes in Stockholders' Equity
Changes in the Bayer Group
Commitments and Contingencies
Compliance Committee
Consolidated Financial Statements
Consolidated Statements of Cash Flows
Consolidation Methods
Contact
Corporate Citizen
Corporate Compliance Program
Corporate Governance
Corporate Governance Code
Corporate Social Responsibility
Corporate Structure
Cost of Materials
Critical Accounting Policies
Currency Risk
Currency Translation
Derivative Financial Instruments
Discontinuing Operations
Distribution
Divestitures
Dividend
Earnings Performance
Earnings per Share
Economic Hedges
Economic Outlook
Employees
Environmental Protection
Exchange Rates
Exchange Rate Risk
Fair Value
Financial Calendar
Financial Instruments
Financial Liabilities
Financial Position
Financial Risks
Financial Strategy
Future Perspectives
Glossary
Goodwill
Governance Bodies
Group Leadership Circle
Hedge Accounting
HSEQ
Human Resources Committee
Impairment
Impairment Testing
Income Statements
Income Taxes
Independent Auditor's Report
Indices
Innovation and Growth
Intangible Assets
Interest Expense – Net
Interest Rate Risk
Inventories
Investor Relations
Key Data by Segment and Region
Key Data by Subgroup
Key Performance Indicators
LANXESS
Leasing
Legal Risks
Liquid Assets
Management Report
Management's Statement of Responsibility for Financial Reporting
Minority Stockholders' Interest in Income/Expence
Mission Statement
Net Debt
Net Income
Non-Operating Result
Notes to the Consolidated Financial Statements
Objectives for 2006
Operating Result
Organization Chart
Other Financial Assets
Other Financial Commitments
Other Non-Operating Expenses
Other Non-Operating Income
Other Operating Expense
Other Operating Income
Other Receivables
Other Taxes
Pensions
Performance by Region
Performance by Segment
Performance by Subgroup
Personnel Expenses
Portfolio Management
Presidial Committee
Primary Financial Instruments
Procurement and Distribution
Property, Plant and Equipment
Proposal for Distribution of the Profit
Provisions
Provisions for Pensions and other Post-Employment Benefits
R&D Expenses
Recognition and Valuation Principles
Regions
Remuneration of the Board of Management
Remuneration of the Supervisory Board
Research and Development
Responsible Care
Restructuring Charges
Risk Management
Salaries (see Remuneration)
Sales
Scope of Consolidation
Segment Reporting
Segments
Selling Expenses
Share Price
Statement of Recognized Income and Expense
Stock-Based Compensation
Stockholders’Equity
Strategy
Subsequent Events
Supervisory Board
Sustainability
Sustainable Development
Sustainable Investment
Ten-Year Financial Summary
Trade Accounts Payable
Trade Accounts Receivable
UNEP
Value-Added
Value Management
Chairman's Letter
Werner Wenning:
“Our efforts have paid off”
New strategic alignment pays off
2005 a successful year for Bayer
Bayer: Science For A Better Life
Inventor Company Bayer
Notice of the Meeting
Annual Stockholders' Meeting on April 28, 2006
– Agenda
– Countermotions
Contact
Search
Sitemap
Deutsch
Bayer Group
Science For A Better Life
Financial Report
Stock
Management Report
Financial Statements
Highlights
Services
Bayer Links
Bayer Global
Investor Relations
Financial Reports 2005
General Conditions of Use
Privacy Statement
Imprint
Technical Details
Download Center
Complete Report
(PDF 4.579 KB)
Download now
Put in Download Center
Services
Order printed edition
Glossary
Calendar
Newsletter
SMS Service
Info
Click
here
for notes on our information package
and all services
.
Bookmark this page
